Tag: biomedical

  • Gene Editing Licensed for Inherited Disease Treatments

    26 October 2015. A Boston biotechnology company is licensing gene-editing technologies from a nearby start-up to design treatments for cystic fibrosis and inherited blood disorders, including sickle cell disease. Vertex Pharmaceuticals, in Boston, received rights to techniques known as CRISPR-Cas9 in a deal that could bring CRISPR Therapeutics, founded in April 2014, as much as…

  • Two Current Drugs Shown Also to Promote Hair Growth

    23 October 2015. Research originally designed to study hair loss from an autoimmune disorder, uncovered two drugs now on the market that in lab tests show they may also regrow hair. Findings of the study led by molecular dermatology professor Angela Christiano at Columbia University in New York appear in today’s issue of the journal…

  • Gene Editing Boosts Red Blood Cell Output in Lab

    23 October 2015. A research team developed a technique with stem cells and gene editing to increase lab production of red blood cells by 3 times, a process that could help people with rare blood types needing transfusions. The researchers led by pediatrics professor Vijay Sankaran at Dana-Farber Cancer Institute and Harvard Medical School published…

  • First Results Released from Lung Fibrosis Registry

    22 October 2015. The first results from a registry of individuals with idiopathic pulmonary fibrosis show most people in the group have limited lung function and show symptoms for about a year before the disease is diagnosed. These findings and other characteristics of people taking part in the Idiopathic Pulmonary Fibrosis – PRospective Outcomes (IPF-PRO)…

  • Trial Testing Aspirin to Prevent Cancer Recurrence

    22 October 2015. A new late-stage clinical trial is underway in the U.K. testing the ability of a daily aspirin to prevent the recurrence of solid tumor cancers. The trial is financed by the advocacy group Cancer Research UK and National Institute for Health Research, a medical research funding agency. The study, led by oncologist…

  • Gates Grant Funding Whooping Cough Antibody Test

    21 October 2015. A protein engineering lab at University of Texas in Austin is evaluating the potential of an engineered antibody to prevent pertussis, also known as whooping cough, among newborn infants. The study and lab are led by chemical engineering professor Jennifer Maynard, who is testing the antibody under a $400,000 grant from the…

  • Delivery Technique Devised to Cross Blood-Brain Barrier

    21 October 2015. Medical researchers developed a technique that allows drugs for treating neurological disorders to penetrate the blood-brain barrier, a difficult obstacle up to now. The team led by ear, nose, and throat, or ENT, specialist Benjamin Bleier at Massachusetts Eye and Ear Hospital and Harvard Medical School described its methods with lab mice…

  • Immunotherapy Start-Up Gains $102M in Venture Funds

    20 October 2015. A new enterprise founded by researchers in the U.S. and Europe that aims to provide personalized cancer therapies harnessing the immune system raised $102 million in its first round of venture financing. The company Gritstone Oncology — in San Francisco and Cambridge, Massachusetts —  says it plans to focus initially on developing…

  • Evotec, Foundation Partner on Rare Juvenile Disease

    20 October 2015. The drug discovery company Evotec AG and Beyond Batten Disease Foundation are collaborating on discovery of new drugs to treat juvenile Batten disease, a rare inherited neurodegenerative disorder. Financial details of the partnership were not revealed. Batten disease is a rare genetic condition of the nervous system that in most cases begins…

  • Novartis Licensing Depression Therapy Technology

    19 October 2015. Luc Therapeutics, a biotechnology company designing treatments for psychiatric and neurological disorders, is licensing part of its technology to the pharmaceutical company Novartis to develop treatments for depression. Dollar amounts paid under the agreement to Luc Therapeutics, in Cambridge, Massachusetts, were not disclosed. Depression is a widespread condition, which when it becomes…